Immunomedics Inc.

Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer

With important work ahead for ADC in lung cancer, Gilead strikes co-development deal with Carlyle-owned life sciences firm

Plus: leadership changes at Valo and more from Mirum, Arvinas, Vaxcyte, Lantern and Inhibikase

Ambitious top-10 goal in cancer by 2030, with BD focus on early-stage assets that add mechanisms to pipeline

Still dwarfed by antivirals, cell therapy unit is key growth driver as Yescarta crosses blockbuster threshold

Over half of the cancer therapies Chinese companies out-licensed in 2021-22 employ new modalities or unapproved targets

Plus new heads of strategy, CMC at Actinium, and updates from Telegraph Hill and Sebela

Jazz pays $50M up front for rights to HER2-targeting bispecific, would owe more than 6x more to retain them after first pivotal readout

Plus IPD spinout Monod Bio raises $25M, Clene looks to Phase III and updates from Gilead, Moderna, Novartis and more

Plus BARDA buys additional monkeypox and smallpox vaccine from Bavarian Nordic, and updates from Fulcrum, ADC, GSK and more